HomeCompareBRNHF vs MRK

BRNHF vs MRK: Dividend Comparison 2026

BRNHF yields 2500.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRNHF wins by $80609755877.31M in total portfolio value
10 years
BRNHF
BRNHF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full BRNHF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BRNHF vs MRK

📍 BRNHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRNHFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRNHF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRNHF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRNHF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BRNHF beats the other by $63,520,143,069,571,610.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRNHF + MRK for your $10,000?

BRNHF: 50%MRK: 50%
100% MRK50/50100% BRNHF
Portfolio after 10yr
$40304877938.71M
Annual income
$37,364,790,040,934,270.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BRNHF
No analyst data
Altman Z
1.0
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRNHF buys
0
MRK buys
0
No recent congressional trades found for BRNHF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRNHFMRK
Forward yield2500.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$80609755877.37M$56.8K
Annual income after 10y$74,729,580,081,858,750.00$9,798.13
Total dividends collected$80198875900.38M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRNHF vs MRK ($10,000, DRIP)

YearBRNHF PortfolioBRNHF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$260,700$250,000.00$11,206$366.19+$249.5KBRNHF
2$6,370,070$6,091,121.50$12,650$502.35+$6.36MBRNHF
3$145,912,632$139,096,656.81$14,407$694.19+$145.90MBRNHF
4$3,133,830,814$2,977,704,297.75$16,585$967.82+$3133.81MBRNHF
5$63,122,812,060$59,769,613,088.96$19,342$1,363.89+$63122.79MBRNHF
6$1,192,683,724,131$1,125,142,315,226.76$22,913$1,947.19+$1192683.70MBRNHF
7$21,144,559,711,004$19,868,388,126,183.19$27,662$2,823.89+$21144559.68MBRNHF
8$351,818,906,448,043$329,194,227,557,269.44$34,159$4,173.35+$351818906.41MBRNHF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$43,337$6,308.80+$5495491397.63MBRNHF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$56,776$9,798.13+$80609755877.31MBRNHF

BRNHF vs MRK: Complete Analysis 2026

BRNHFStock

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

Full BRNHF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BRNHF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRNHF vs SCHDBRNHF vs JEPIBRNHF vs OBRNHF vs KOBRNHF vs MAINBRNHF vs JNJBRNHF vs ABBVBRNHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.